HypercholerolemiaPhase 1NCT07581028
Bioequivalence Study of AJU-C715 and C715R in Healthy Adult Volunteers
A Phase 1 study testing Test Drug and Reference Drug in people with Hypercholerolemia and Dyslipidemia, run by AJU Pharm Co., Ltd. at 1 site in South Korea.
Trial summary
To Evaluate the Safety and Pharmacokinetics of "AJU-C715" and "C715R" in Healthy Adults. Read more about this study
- Who is it for?
- Ages 19 to 59 yearsHealthy volunteers can take part
- Conditions the study is for
- Hypercholerolemia, Dyslipidemia
- What is being tested?
- Test Drug and Reference Drug
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 61 participants
- Where
- 1 siteSouth Korea
- Study dates
- 6 Aug 2026to 28 Aug 2026
- Phase
- Phase 1
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 19 to 59 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Healthy adults aged 19 to less than 60 years at the time of screening
- Weight ≥ 50 kg for men or ≥ 45 kg for women, with a calculated body mass index(BMI) of 18 to 30 kg/m² at the time of screening.
- Those who have no congenital chronic disease or chronic disease requiring treatment and who have no pathological symptoms or findings.
- Those who are eligible for the clinical trial based on laboratory test results(hematology, blood chemistry, serum, and urine tests) and 12-lead ECG findings during screening.
- Those who voluntarily decide to participate and agree to comply with the cautions after hearing and fully understanding the detailed description of this clinical trial.
- Those who agree to use highly effective methods of contraception(excluding hormonal methods) to prevent pregnancy, either for themselves or their spouse/partner, from the first administration of the investigational medicinal product until one week after the last administration, and who agree not to donate sperm or eggs during this period.
Who cannot join
- Those who take barbiturate and related (causing induction or inhibition of metabolism) drug within 1 month or the first administration of clinical trial drug within 10 days.
- Those who received investigational product or bioequivalence test drug within 6 months before the first administration of clinical trial drug. 3. Those who donated whole blood within 8 weeks, received apheresis within 2 weeks, blood transfusion within 1 month or can't refrain from donating blood from the time of written consent until the end of the study.
- 4. Those who has a history of gastrointestinal disease or surgery which may affect the absorption of the drug.
- 5. Those who exceeding an alcohol consumption criteria Alcohol: Men - 21 glass/week, Women - 14 glass/week (1 glass: Soju 50 mL, Beer 250mL or liquor: 30mL), Smoke: 20 cigarettes/day.
- 6. Those who has under
- Those who are hypersensitive to component of the Investigational product and have the medical history
Show all 12Show fewer
- Those with active liver disease or persistent elevation of aminotransferase levels of unknown
- Those taking cyclosporin
- Those with Myopathy
- Those with severe Renal Impairment due to Renal Failure
- Those who has Genetic problems such as galactose intolerance, Lapp lactose deficiency or glucose-galactose malabsorption 7. Those who has a history of mental illness. 8. Those who are deemed unfit by the investigators to participate in the clinical trial for other reasons.
- 9. Women who are pregnant or who may be pregnant and breastfeed.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: An Open-Label, Randomized, Fasting, Single-Dose, Two-Sequence, Two-Period Crossover Study to Evaluate the Bioequivalence of "AJU-C715" and "C715R" in Healthy Adult Volunteers
To Evaluate the Safety and Pharmacokinetics of "AJU-C715" and "C715R" in Healthy Adults.
- Conditions
- Hypercholerolemia, Dyslipidemia
- Being tested
- Test Drug, Reference Drug
- Medical subject headings
- Dyslipidemias
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Test DrugDrug
AJU-C715
Reference DrugDrug
C715R
| Study group | Role | What they receive |
|---|---|---|
| Sequence A | Experimental | Period 1: Reference Drug, Single dose/ Period 2: Test Drug, Single dose Receives: Drug: Test Drug; Drug: Reference Drug |
| Sequence B | Experimental | Period 1: Test Drug, Single dose/ Period 2: Reference Drug, Single dose Receives: Drug: Test Drug; Drug: Reference Drug |
What is being measured
The primary outcome is the main question the study is designed to answer.
AUCt of AJU-C715
Measured: Pre-dose(0 hours) ~ 72 hours
Cmax of AJU-C715
Measured: Pre-dose(0 hours) ~ 72 hours
Secondary outcomes (4)
AUC∞ of AJU-C715
Measured: Pre-dose(0 hours) ~ 72 hours
AUCt/AUC∞ of AJU-C715
Measured: Pre-dose(0 hours) ~ 72 hours
Tmax of AJU-C715
Measured: Pre-dose(0 hours) ~ 72 hours
t1/2 of AJU-C715
Measured: Pre-dose(0 hours) ~ 72 hours
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 May 2026
- Study start6 Aug 2026
- Primary completion24 Aug 2026
- Study completion28 Aug 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for HypercholerolemiaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Enrolment
- 61 participants (actual)
Sponsor and investigators
- Lead sponsor
- AJU Pharm Co., Ltd.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07581028
- Sponsor's protocol ID
- 26PHL10105
- Status last verified
- Sep 2026
- First submitted
- 6 May 2026
- Last updated
- 9 Sep 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 9 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- An Open-Label, Randomized, Fasting, Single-Dose, Two-Sequence, Two-Period Crossover Study to Evaluate the Bioequivalence of "AJU-C715" and "C715R" in Healthy Adult Volunteers
- ClinicalTrials.gov ID
- NCT07581028
- Acronym / sponsor ID
- 26PHL10105
- Conditions
- Hypercholerolemia, Dyslipidemia
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 61 participants (actual)
- Lead sponsor
- AJU Pharm Co., Ltd.Industry (pharma, biotech, devices)
- Study start
- 6 Aug 2026 (actual)
- Primary completion
- 24 Aug 2026 (actual)
- Study completion
- 28 Aug 2026 (actual)
- First posted
- 12 May 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
To Evaluate the Safety and Pharmacokinetics of "AJU-C715" and "C715R" in Healthy Adults.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Sequence A | Experimental | Drug: Test Drug, Drug: Reference DrugPeriod 1: Reference Drug, Single dose/ Period 2: Test Drug, Single dose |
| Sequence B | Experimental | Drug: Test Drug, Drug: Reference DrugPeriod 1: Test Drug, Single dose/ Period 2: Reference Drug, Single dose |
Who may qualify
- Ages
- 19 to 59 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (6 listed)
- Healthy adults aged 19 to less than 60 years at the time of screening
- Weight ≥ 50 kg for men or ≥ 45 kg for women, with a calculated body mass index(BMI) of 18 to 30 kg/m² at the time of screening.
- Those who have no congenital chronic disease or chronic disease requiring treatment and who have no pathological symptoms or findings.
- Those who are eligible for the clinical trial based on laboratory test results(hematology, blood chemistry, serum, and urine tests) and 12-lead ECG findings during screening.
- Those who voluntarily decide to participate and agree to comply with the cautions after hearing and fully understanding the detailed description of this clinical trial.
Key exclusion criteria (12 listed)
- Those who take barbiturate and related (causing induction or inhibition of metabolism) drug within 1 month or the first administration of clinical trial drug within 10 days.
- Those who received investigational product or bioequivalence test drug within 6 months before the first administration of clinical trial drug. 3. Those who donated whole blood within 8 weeks, received apheresis within 2 weeks, blood transfusion within 1 month or can't refrain from donating blood from the time of written consent until the end of the study.
- 4. Those who has a history of gastrointestinal disease or surgery which may affect the absorption of the drug.
- 5. Those who exceeding an alcohol consumption criteria Alcohol: Men - 21 glass/week, Women - 14 glass/week (1 glass: Soju 50 mL, Beer 250mL or liquor: 30mL), Smoke: 20 cigarettes/day.
- 6. Those who has under
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Test DrugAJU-C715 | Drug | Sequence A, Sequence B |
| Reference DrugC715R | Drug | Sequence A, Sequence B |
Primary outcome
AUCt of AJU-C715
Time frame: Pre-dose(0 hours) ~ 72 hours
Cmax of AJU-C715
Time frame: Pre-dose(0 hours) ~ 72 hours
4 secondary outcomes
AUC∞ of AJU-C715
Time frame: Pre-dose(0 hours) ~ 72 hours
AUCt/AUC∞ of AJU-C715
Time frame: Pre-dose(0 hours) ~ 72 hours
Tmax of AJU-C715
Time frame: Pre-dose(0 hours) ~ 72 hours
t1/2 of AJU-C715
Time frame: Pre-dose(0 hours) ~ 72 hours
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 Sep 2026.
Related trials for Hypercholerolemia
Not yet recruiting
Tracking Income Dynamics and Everyday Health Study
HIV, Hypertension
RecruitingObservational study
Cardiovascular-kidney-metabolic (CKM)-Guided Therapy for Patients After Acute Coronary Syndrome
Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI), Hypercholerolemia
RecruitingObservational study
Effects of Statins and Hormone Replacement Therapy in Coagulation Profile of Menopausal Women With Dyslipidemia
Menopausal Complaints, Hypercholerolemia
Not yet recruitingObservational study
Faisalabad Initiative of Research and Management of NCDs
Diabete Mellitus, Hypertension
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing Test Drug and Reference Drug in people with Hypercholerolemia and Dyslipidemia, run by AJU Pharm Co., Ltd. at 1 site in South Korea.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 12 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 9 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in South Korea. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
AUCt of AJU-C715 (time frame: Pre-dose(0 hours) ~ 72 hours). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Sep 2026.